Quality-of-life and health benefits of early treatment of mild anemia: A randomized trial of epoetin alfa in patients receiving chemothepy for hematologic malignancies Academic Article uri icon

Overview

MeSH Major

  • Anemia
  • Antineoplastic Agents
  • Erythropoietin
  • Hematologic Neoplasms
  • Quality of Life

abstract

  • Treating mild anemia immediately with epoetin alfa during chemotherapy for hematologic malignancy significantly improved QOL, productivity, and hemoglobin compared with delaying treatment until the hemoglobin level decreases to < 9.0 g/dL.

publication date

  • October 15, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.22221

PubMed ID

  • 16977654

Additional Document Info

start page

  • 1909

end page

  • 17

volume

  • 107

number

  • 8